David Bredt, Chief Scientific Officer: Rapport Therapeutics RAPP Sell · Filed 25/09/17

Trade details

Type: Insider sale
Amount: $121,740.24
Shares · price: 5,098 sh · $23.88 a share
Held after: 421,544 sh
Stock: Rapport Therapeutics RAPP
Person: David BredtChief Scientific Officer
Trade date: 25/09/15
Filed: 25/09/17
Days to filing: 2 days

Sold 1.2% of holdings

Share of holding sold: 1.2%

Rapport Therapeutics trades, last 26 weeks

What else happened in Rapport Therapeutics around then

Filed or reported within 30 days of the trade day · 25/08/16~25/10/15

David Bredt's recent trades

David BredtChief Scientific Officer
Sell10b5-1 planRapport Therapeutics
Sell10b5-1 plan
Rapport Therapeutics
RAPP
$156.3K
5,400 sh
$156.3K
Filed 02/19
Traded 02/17
David BredtChief Scientific Officer
Sell10b5-1 planRapport Therapeutics
Sell10b5-1 plan
Rapport Therapeutics
RAPP
$65.1K
2,200 sh
$65.1K
Filed 02/19
Traded 02/17
David BredtChief Scientific Officer
Sell10b5-1 planRapport Therapeutics
Sell10b5-1 plan
Rapport Therapeutics
RAPP
$25.2K
900 sh
$25.2K
Filed 02/19
Traded 02/17
David BredtChief Scientific Officer
Sell10b5-1 planRapport Therapeutics
Sell10b5-1 plan
Rapport Therapeutics
RAPP
$222.7K
8,300 sh
$222.7K
Filed 01/16
Traded 01/15
David BredtChief Scientific Officer
Sell10b5-1 planRapport Therapeutics
Sell10b5-1 plan
Rapport Therapeutics
RAPP
$5,480
200 sh
$5,480
Filed 01/16
Traded 01/15

David Bredt, Chief Officer — sold $121.7K of Rapport Therapeutics RAPP · 1.2% of holdings · 10b5-1 plan | Whalegun